Citations

Mayo Clinic

Showing 10 of 108585 citations.

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Goetz, Matthew P. , Hamilton, Erika , Campone, Mario , Hurvitz, Sara A. , Cortés, Javier , Johnston, Stephen , Llombart‐Cussac, Antonio , Kaufman, Peter A. , Toi, Masakazu , Jérusalem, Guy , Graham, Hillary , Wang, Hong , Jansen, Valerie M. , Litchfield, Lacey M. , Hamilton, Erika P , Martin, Miguel , Goetz, Matthew P , Johnston, Stephen , Jerusalem, Guy , Martín, Miguel , Cortés, J.

Clinical Cancer Research | October 27, 2023 | Volume: 30 | Issue: 10 | Pages: 2233-2244

10.1158/1078-0432.ccr-22-3573 | PMID 37889120 Get It

Abstract Purpose: To identify potential predictors of response and resistance mechanisms in patients with hormone receptor–positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) treated with the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor abemaciclib ± endocrine therapy (ET), baseline and acquired genomic alterations in circulating tumor DNA (ctDNA) were analyzed and associated with clinical outcomes. Experimental Design: MONARCH 3: postmenopausal women with HR+, HER2− ABC and no prior systemic therapy in the advanced setting were randomly assigned to abemaciclib or placebo plus nonsteroidal aromatase inhibitor (NSAI). nextMONARCH: women with HR+, HER2− metastatic breast cancer that progressed on/after prior ET and chemotherapy were randomly assigned to abemaciclib alone (two doses) or plus tamoxifen. Baseline and end-of-treatment plasma samples from patients in MONARCH 3 and nextMONARCH (monotherapy arms) were analyzed to identify somatic genomic alterations. Association between genomic alterations and median progression-free survival (mPFS) was assessed. Results: Most patients had ≥1 genomic alteration detected in baseline ctDNA. In MONARCH 3, abemaciclib+NSAI was associated with improved mPFS versus placebo+NSAI, regardless of baseline alterations. ESR1 alterations were less frequently acquired in the abemaciclib+NSAI arm than placebo+NSAI. Acquired alterations potentially associated with resistance to abemaciclib ± NSAI included RB1 and MYC. Conclusions: In MONARCH 3, certain baseline ctDNA genomic alterations were prognostic for ET but not predictive of abemaciclib response. Further studies are warranted to assess whether ctDNA alterations acquired during abemaciclib treatment differ from other CDK4/6 inhibitors. Findings are hypothesis generating; further exploration is warranted into mechanisms of resistance to abemaciclib and ET. See related commentary by Wander and Bardia, p. 2008
Using Group Concept Mapping to Explore Medical Education’s Blind Spots
Tackett, Sean , Steinert, Yvonne , Mirabal, Susan , Reed, Darcy A. , Wright, Scott M. , Mirabal, Susan , Wright, Scott M

Teaching and Learning in Medicine | October 27, 2023 | Volume: 37 | Issue: 1 | Pages: 75-85

10.1080/10401334.2023.2274991 | PMID 37886902 Get It

Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
Bergeman, Auke T. , Lieve, Krystien V.V. , Kallas, Dania , Bos, J. Martijn , Noguer, Ferran Rosés i, Denjoy, Isabelle , Zorio, Esther , Kammeraad, Janneke A.E. , Peltenburg, Puck J. , Tobert, Katie, Aiba, Takeshi , Batra, Anjan S. , Borggrefe, Martin , Cox, Moniek G.P.J. , Dhillon, Santokh , Etheridge, Susan P. , Fischbach, Peter , Franciosi, Sonia , Horie, Minoru , Johnsrude, Christopher L. , Kane, Austin, Krause, Ulrich , Kwok, Sit‐Yee , Ohno, Seiko , Roberts, Jason D. , Robyns, Tomas , Sacher, Frédéric , Semsarian, Christopher , Swan, Heikki, Tavačová, Terézia , Tisma‐Dupanovic, Svjetlana , Tfelt‐Hansen, Jacob , Yap, Sing‐Chien , Till, Janice, Sanatani, Shubhayan , Ackerman, Michael J. , Wilde, Arthur A.M. , Rosés‐Noguer, Ferran , Atallah, Joseph , Drago, Fabrizio , Brugada, Ramón , Borggrefe, Martin , Clur, Sally-Ann B , Cox, Moniek G P J , Davis, Andrew , Dhillon, Santokh , Etheridge, Susan P , Haugaa, Kristina , Horie, Minoru , Johnsrude, Christopher , Krause, Ulrich , LaPage, Martin J , Ohno, Seiko , Probst, Vincent , Roberts, Jason D , Robyns, Tomas , Sacher, Frederic , Semsarian, Christopher , Skinner, Jonathan R , Tavacova, Terezia , Tisma-Dupanovic, Svjetlana , Tfelt-Hansen, Jacob , Yap, Sing-Chien , Kannankeril, Prince J , Leenhardt, Antoine , Sanatani, Shubhayan , Ackerman, Michael J , Wilde, Arthur A M , van der Werf, Christian , Bos, Johan M , Zorio, Esther , Denjoy, Isabelle , Rosés-Noguer, Ferran , Kammeraad, Janneke A E , Lieve, Krystien V , Peltenburg, Puck J , Aiba, Takeshi , Atallah, Joseph , Clur, Sally‐Ann B. , Davis, Andrew M. , Haugaa, Kristina H. , Skinner, Jonathan R. , Kannankeril, Prince J. , Leenhardt, Antoine , Tanck, Michael , Werf, Christian van der , Bergeman, Auke T

Circulation | October 27, 2023 | Volume: 148 | Issue: 25 | Pages: 2029-2037

10.1161/circulationaha.123.064786 | PMID 37886885 Get It

BACKGROUND: In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia. METHODS: From 2 international registries, this multicenter case cross-over study included patients with a clinical or genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia in whom flecainide was added to beta-blocker therapy. The study period was defined as the period in which background therapy (ie, beta-blocker type [beta1-selective or nonselective]), left cardiac sympathetic denervation, and implantable cardioverter defibrillator treatment status, remained unchanged within individual patients and was divided into pre-flecainide and on-flecainide periods. The primary end point was AEs, defined as sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter defibrillator shock, and arrhythmic syncope. The association of flecainide with AE rates was assessed using a generalized linear mixed model assuming negative binomial distribution and random effects for patients. RESULTS: A total of 247 patients (123 [50%] females; median age at start of flecainide, 18 years [interquartile range, 14–29]; median flecainide dose, 2.2 mg/kg per day [interquartile range, 1.7–3.1]) were included. At baseline, all patients used a beta-blocker, 70 (28%) had an implantable cardioverter defibrillator, and 21 (9%) had a left cardiac sympathetic denervation. During a median pre-flecainide follow-up of 2.1 years (interquartile range, 0.4–7.2), 41 patients (17%) experienced 58 AEs (annual event rate, 5.6%). During a median on-flecainide follow-up of 2.9 years (interquartile range, 1.0–6.0), 23 patients (9%) experienced 38 AEs (annual event rate, 4.0%). There were significantly fewer AEs after initiation of flecainide (incidence rate ratio, 0.55 [95% CI, 0.38–0.83]; P =0.007). Among patients who were symptomatic before diagnosis or during the pre-flecainide period (n=167), flecainide was associated with significantly fewer AEs (incidence rate ratio, 0.49 [95% CI, 0.31–0.77]; P =0.002). Among patients with ≥1 AE on beta-blocker therapy (n=41), adding flecainide was also associated with significantly fewer AEs (incidence rate ratio, 0.25 [95% CI, 0.14–0.45]; P <0.001). CONCLUSIONS: For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.
Partial Denervation of the Thumb Carpometacarpal Joint: A New Technique
Lui, Hayman , Kakar, Sanjeev , Vaquette, Cedryck , Kakar, Sanjeev

HAND | October 27, 2023 | Volume: 20 | Issue: 2 | Pages: 224-229

10.1177/15589447231200646 | PMID 37888777 Get It

Background: To report the clinical outcomes of partial denervation for the treatment of basilar thumb joint arthritis. Methods: Patients who underwent partial denervation of the basilar thumb joint for osteoarthritis from a single center between 2019 and 2021 were recruited into the study. This involved a technique that involved cauterization of the joint capsule and its innervation through the branches of the superficial radial, palmar cutaneous branch of the median, lateral antebrachial, and ulnar nerves. Patients were followed up postoperatively to record clinical (grip strength, thumb apposition and opposition pinch grip strength, Kapandji score) and patient-reported outcomes (visual analogue scale [VAS], Quick Disabilities of the Arm, Shoulder and Hand [QuickDASH], Patient-reported Wrist Evaluation [PRWE]). Results: Twelve patients (15 carpometacarpal joints; 9 female and 3 male patients) underwent a partial denervation of the thumb (Eaton stage 3-4). The mean age at the time of surgery was 63 ± 5 years (range 56-72). The mean clinical follow-up duration was 23 ± 11 months (range 9-42 months), and functional score follow-up duration was 27 ± 7 months (range 14-42 months). At the latest clinical follow, VAS score, Kapandji score, grip strength, and thumb apposition/opposition pinch strength all improved significantly ( P < .05). The mean QuickDASH score was 30 ± 16, and PRWE score was 32 ± 17. Patients who had unilateral partial thumb denervation demonstrated greater improvement in grip strength than patients who had bilateral partial thumb denervation procedures ( P = .01). Conclusion: In this clinical case series, our method of basilar thumb joint partial denervation has been effective in improving clinical outcomes and reducing pain due to osteoarthritis. Level of Evidence: IV, case series
The Association between Non-Invasive Ventilation and the Rate of Ventilator-Associated Pneumonia
Saunders, Hollie , Khadka, Subekshya, Shrestha, Rabi , Balavenkataraman, Arvind , Hochwald, Alexander , Ball, Colleen T. , Helgeson, Scott A. , Helgeson, Scott A , Shrestha, Rabi

Diseases | October 27, 2023 | Volume: 11 | Issue: 4 | Pages: 151

10.3390/diseases11040151 | PMID 37987262 Get It

Ventilator-associated pneumonia (VAP) has significant effects on patient outcomes, including prolonging the duration of both mechanical ventilation and stay in the intensive care unit (ICU). The aim of this study was to assess the association between non-invasive ventilation/oxygenation (NIVO) prior to intubation and the rate of subsequent VAP. This was a multicenter retrospective cohort study of adult patients who were admitted to the medical ICU from three tertiary care academic centers in three distinct regions. NIVO was defined as continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or high-flow nasal cannula (HFNC) for any duration during the hospitalization prior to intubation. The primary outcome variable was VAP association with NIVO. A total of 17,302 patients were included. VAP developed in 2.6% of the patients (444/17,302), 2.3% (285/12,518) of patients among those who did not have NIVO, 1.6% (30/1879) of patients who had CPAP, 2.5% (17/690) of patients who had HFNC, 8.1% (16/197) of patients who had BiPAP, and 4.8% (96/2018) of patients who had a combination of NIVO types. Compared to those who did not have NIVO, VAP was more likely to develop among those who had BiPAP (adj OR 3.11, 95% CI 1.80–5.37, p < 0.001) or a combination of NIVO types (adj OR 1.91, 95% CI 1.49–2.44, p < 0.001) after adjusting for patient demographics and comorbidities. The use of BiPAP or a combination of NIVO types significantly increases the odds of developing VAP once receiving IMV.
First pass effect as an independent predictor of functional outcomes in medium vessel occlusions: An analysis of an international multicenter study
Radu, Răzvan Alexandru , Costalat, Vincent , Fahed, Robert , Ghozy, Sherief , Shaikh, Hamza , Khalife, Jane , Abdalkader, Mohamad , Klein, Piers , Nguyen, Thanh N. , Heit, Jeremy J. , Regenhardt, Robert W. , Diestro, Jose Danilo Bengzon , Cancelliere, Nicole M , Amllay, Abdelaziz , Dusart, Anne , Bellante, Flavio, Rouchaud, Aymeric , Puri, Ajit S., Dyzmann, Christian , Kan, Peter , Colasurdo, Marco , Berge, Jérôme , Barreau, Xavier , Nedelcu, Simona , Henninger, Nils , Kyheng, Maéva , Marotta, Thomas R. , Stapleton, Christopher J. , Rabinov, James D. , Dofuku, Shogo , Tan, Benjamin Yong‐Qiang , Salazar‐Marioni, Sergio , Capirossi, Carolina , Mowla, Ashkan , Tjoumakaris, Stavropoula I, Khandelwal, Priyank , Biswas, Arundhati , Clarençon, Frédéric , Elhorany, Mahmoud , Premat, Kévin , Valente, Iacopo , Filipe, João Pedro , Varela, Ricardo , Quintero‐Consuegra, Miguel , Gonzalez, Nestor R. , Möhlenbruch, Markus , Tancredi, Illario , Yedavalli, Vivek , Chervak, Lina , Aziz, Yasmin , Stracke, Christian Paul , Hecker, Constantin , Hsieh, Cheng‐Yang , Liebeskind, David S. , Alexandre, Andrea , Faizy, Tobias D. , Patel, Aman B. , Lubicz, Boris , Guenego, Adrien , Klein, Piers , Nguyen, Thanh N , Heit, Jeremy J , Sweid, Ahmad , Bellante, Flavio , Forestier, Géraud , Kühn, Anna Luisa , Marnat, Gaultier , Ota, Takahiro , Dofuku, Shogo , Yeo, Leonard Ll , Salazar-Marioni, Sergio , Jabbour, Pascal , Gonzalez, Nestor R , Möhlenbruch, Markus A , Jesser, Jessica , Aziz, Yasmin , Faizy, Tobias D , Liebeskind, David S. , Ghozy, Sherief , Diestro, Jose Danilo B , Regenhardt, Robert W , Alexandru Radu, Răzvan , Fahed, Robert , Yedavalli, Vivek S , Cancelliere, Nicole M , Rouchaud, Aymeric , Colasurdo, Marco , Hecker, Constantin , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Mowla, Ashkan , Varela, Ricardo , Siegler, James E. , Naamani, Kareem El , Meyer, Lukas , Forestier, Géraud , Saleme, Suzana , Mounayer, Charbel , Fiehler, Jens , Kühn, Anna Luisa , Puri, Ajit S , Sibon, Igor , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Renieri, Leonardo , Tjoumakaris, Stavropoula , Jabbour, Pascal , Khandelwal, Priyank , Pedicelli, Alessandro , Schiphorst, Adrien ter , Harker, Pablo , Gory, Benjamin , Killer-Oberpfalzer, Monika , Griessenauer, Christoph J. , Thomas, Ajith J , Weyland, Charlotte S. , Mendes Pereira, Vitor , Dmytriw, Adam A.

European Stroke Journal | October 27, 2023 | Volume: 9 | Issue: 1 | Pages: 114-123

10.1177/23969873231208276 | PMID 37885243 Get It

Abstract Introduction: First pass effect (FPE), achievement of complete recanalization (mTICI 2c/3) with a single pass, is a significant predictor of favorable outcomes for endovascular treatment (EVT) in large vessel occlusion stroke (LVO). However, data concerning the impact on functional outcomes and predictors of FPE in medium vessel occlusions (MeVO) are scarce. Patients and Methods: We conducted an international retrospective study on MeVO cases. Multivariable logistic modeling was used to establish independent predictors of FPE. Clinical and safety outcomes were compared between the two study groups (FPE vs non-FPE) using logistic regression models. Good outcome was defined as modified Rankin Scale 0–2 at 3 months. Results: Eight hundred thirty-six patients with a final mTICI ⩾ 2b were included in this analysis. FPE was observed in 302 patients (36.1%). In multivariable analysis, hypertension (aOR 1.55, 95% CI 1.10–2.20) and lower baseline NIHSS score (aOR 0.95, 95% CI 0.93–0.97) were independently associated with an FPE. Good outcomes were more common in the FPE versus non-FPE group (72.8% vs 52.8%), and FPE was independently associated with favorable outcome (aOR 2.20, 95% CI 1.59–3.05). 90-day mortality and intracranial hemorrhage (ICH) were significantly lower in the FPE group, 0.43 (95% CI, 0.25–0.72) and 0.55 (95% CI, 0.39–0.77), respectively. Conclusion: Over 2/3 of patients with MeVOs and FPE in our cohort had a favorable outcome at 90 days. FPE is independently associated with favorable outcomes, it may reduce the risk of any intracranial hemorrhage, and 3-month mortality.
Creation of a Novel, Race-Adjusted, and Risk-Adapted Scoring System to Predict Positive Surgical Margins and Prolonged Operative Time During Robotic Radical Prostatectomy
Thakker, Parth , Hemal, Ashok K. , Geldmaker, Laura , Ball, Colleen T. , Pak, Raymond , Pathak, Ram A. , Lyon, Timothy, Pathak, Ram Anil, Lyon, Timothy D.

Journal of Endourology | October 27, 2023 | Volume: 38 | Issue: 1 | Pages: 40-46

10.1089/end.2023.0210 | PMID 37885199 Get It

Timing of Ureteral Stent Removal After Ureteroscopy on Stent-Related Symptoms: A Validated Questionnaire Comparison of 3 and 7 Days Stent Duration
Heidenberg, Daniel , Nauheim, Jennifer, Grant, Campbell , Mi, Lanyu , Walt, Charles Van Der , Mufarrij, Patrick, Heidenberg, Daniel J, Van der Walt, Charles

Journal of Endourology | October 27, 2023 | Volume: 38 | Issue: 1 | Pages: 82-87

10.1089/end.2023.0189 | PMID 37885220 Get It

Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial
Koschel, Dirk, Flaherty, Kevin R. , Wells, Athol U. , Devaraj, Anand, Walsh, Simon , Moua, Teng , Goeldner, Rainer-Georg , Schlenker‐Herceg, Rozsa, Brown, Kevin K. , Cottin, Vincent , Inoue, Yoshikazu , Richeldi, Luca , Kolb, Martin R.J. , Stowasser, Susanne

Pneumologie | October 26, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0041-1723315 Get It

First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Scherpereel, Arnaud , Antonia, Scott , Bautista, Y., Zalcman, Gérard , Sun, Xuezheng , Padilla, Brad , Aanur, Praveen , Daumont, M. , Bennett, Bryan , McKenna, M., Baas, P, Zalcman, Gérard , Bischoff, Hervé , Grossi, Francesco , Kowalski, Dariusz M. , Nowak, Anna K. , Fujimoto, Nobukazu , Peters, Solange , Tsao, Anne S. , Mansfield, Aaron S. , Popat, Sanjay , Bennett, B, Baas, P

Pneumologie | October 26, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0041-1723293 Get It